Seven children’s hospitals across the United States are collaborating to rapidly integrate genetics and genomics into primary and specialty pediatric care.
The mission of the Sanford Children’s Genomic Medicine Consortium is to work together on innovative clinical program development, advocacy for children, cutting-edge research and educational programs for the future of genomic medicine.
Participating hospitals are spread across the country
The seven member-hospitals include: Sanford Children’s (Sioux Falls and Fargo), Children’s Minnesota (Minneapolis and St. Paul), Children’s Hospital Colorado (Aurora), Children’s Hospital Los Angeles, Rady Children’s Institute for Genomic Medicine and Rady Children’s Hospital - San Diego, Banner Children’s at Diamond Children’s Medical Center (Tucson) and Nicklaus Children’s Hospital (Miami).
Sanford Health has provided $500,000 in seed funding for consortium projects over the next year.
The initial projects funded by the consortium include a study of rapid whole genomic sequencing in critically ill newborn infants, and a study evaluating the routine use of an extensive, pediatric-focused, next-generation sequencing panel in the diagnosis of childhood cancers.
Significant progress in the diagnosis of genetic diseases
Genetic diseases are a leading cause of morbidity and mortality in infants in Neonatal and Pediatric Intensive Care Units (NICU, PICU). These children often undergo an extensive and expensive diagnostic process that may not lead to a final diagnosis. Stephen Kingsmore, M.D., D.Sc., president and CEO of Rady Children’s Institute of Genomic Medicine (RCIGM) is leading rapid whole genomic sequencing in critically ill newborn infants to determine the complete DNA sequence of a child’s genome at one time to identify the risk of genetic diseases. Currently, the average turn-around time for sequencing to diagnosis by the RCIGM team is under a week. That is significantly faster than the common timetable for this type of work, which can take weeks to complete.
Rapid diagnosis could lead to targeted treatment
“The future of pediatric medicine is being transformed by the ability to rapidly decode the genomes of the most fragile newborns to deliver exact diagnoses and targeted treatment,” said Kingsmore.
Pediatric cancers have different genetic origins compared with adult cancers. Current panels for detecting the genetic origins of a tumor primarily focus on adult cancers. OncoKidsSM developed at Children’s Hospital Los Angeles, is specifically formulated to detect the genomic alterations of pediatric cancers including leukemias, lymphomas, bone, soft tissue and brain tumors.
Extending precision medicine to pediatric cancer treatment
“The ability to identify the precise underlying genomic alterations in individual tumors with OncoKidsSM allows us to personalize care and innovate how we treat children with cancer,” said Alexander R. Judkins, M.D., Pathologist-in-Chief and Executive Director of the Center for Personalized Medicine (CPM) at Children’s Hospital Los Angeles.
Extending precision medicine to children’s health through this consortium is inspired by the vision of Denny Sanford. In 2014, the health care philanthropist gave $125 million to Sanford Health to create Sanford Imagenetics, the first program in the nation to embed the latest in genomic medicine with primary care.
“I am thankful to each member for their participation in the Sanford Children’s Genomic Medicine Consortium,” said Gene Hoyme, M.D., Medical Director, Sanford Children’s Genomic Medicine Consortium. “So much can be gained for the care of children through the collaboration of these hospitals.”